Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - NeuBase Therapeutics, Inc. | ohrp_ex991.htm |
| EX-10.16 - EMPLOYMENT AGREEMENT - NeuBase Therapeutics, Inc. | ohrp_ex1016.htm |
| EX-10.17 - EMPLOYMENT AGREEMENT - NeuBase Therapeutics, Inc. | ohrp_ex1017.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest
event reported): April 12, 2009
| Ohr Pharmaceutical, Inc. | ||
| (Exact name of registrant as specified in its charter) |
|
Delaware
|
333-88480
|
#04-3648721
|
||
|
(State
or other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
489
5th Ave, 28th Floor, New York, NY
|
10017
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (212)-682-8452
|
1245
Brickyard Rd. Suite 590, Salt Lake City, Utah
84106
|
|
(Former
name or former address if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 1.01. ENTRY INTO A
MATERIAL DEFINITIVE AGREEMENT.
On April
8, 2009, the Registrant entered into an Employment Agreement with Dr. Irach
Taraporewala who will serve as Chief Executive Officer and Mr. Sam Backenroth
who will serve as Vice President of Business Development and Interim Chief
Financial Officer. In connection with the employment agreements the Registrant
received a letter of Resignation from Mr. Andrew Limpert who is resigning from
his positions as Interim Chief Executive Officer, Chief Financial Officer and
Board Director. A copy of the press release regarding the management change is
attached hereto as Exhibit 99.1, and is incorporated herein by
reference.
ITEM
9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit
No. Description
---------- -------------------------------------------------------------------
10.16 Employment
Agreement with Dr. Irach Taraporewala
10.17 Employment
Agreement with Mr. Sam Backenroth
99.1 Press
Release Dated April 12, 2010
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| OHR PHARMACEUTICAL, INC. | |||
|
Dated:
April 12, 2010
|
By:
|
/s/Irach Taraporewala | |
| Dr. Irach Taraporewala, President and CEO | |||
3